Skip to content

Clinical Investigation of ReLEx hismile with the VisuMax femtosecond laser system

Clinical Investigation of ReLEx hismile with the VisuMax femtosecond laser system

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00006141
Enrollment
48
Registered
2014-06-27
Start date
2015-03-02
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H52

Interventions

Group 1: ReLEx hismile: Refractive correction of myopia and myopia with astigmatism with the VisuMax femtosecond laser system by an aspheric design of the corneal lenticule Group 2: ReLEx smile: Histo

Sponsors

Carl Zeiss Meditec AG
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: -Subjects should be 18 years of age or older -Calculated residual stromal thickness (RST)>250 µm -Normal corneal topography - Contact lens wearers must stop wearing their rigid or soft contact lenses before baseline measurements according to local requirements of the clinic -Distance refraction must be stable within the last twelve months -only myopic patients or patients with myopia and astigmatism (sphere within -0.50D to -10.00D, cylinder up to 5.00D) -The corrected distance visual acuity shall be 20/25 or better in each eye pre-operatively. -Patients with a wavefront analysis diameter of at least 5mm (undilated) pre-OP -Patient shall be able to understand the patient information and willing to sign an informed consent -Patient shall be willing to comply with all follow-up visits

Exclusion criteria

Exclusion criteria: • Previous intraocular or corneal surgery of any kind on the eye being treated. • Intake of systemic medications which affect wound healing (e.g. corticosteroids) • Treatment with medications such as steroids or immune-suppressants • Diagnosis of an autoimmune disease, connective tissue disease or diabetes • Unstable central keratometry readings with irregularities • Herpes simplex or herpes zoster keratitis • The patient is not able to lie flat in a horizontal position • The patient cannot make him/herself understood and react to instructions • The patient does not tolerate local or topical anaesthesia • Pregnant or nursing women (or women, who planning pregnancy during the study) • Any residual, recurrent or acute ocular disease or abnormality of the eye, e.g. – Cataract – Suspected glaucoma or an intraocular pressure >21 mm of Hg – Corneal disease – Corneal thinning disorder, e.g. keratoconus, – Pellucid marginal corneal degeneration – Dystrophy of the basal membrane – Corneal oedema – Exudative macular degeneration – Infection Any residual, recurrent, or active abnormality of the cornea to be treated, e.g. - Existing corneal implant - Corneal lesion - Unstable refraction - Connective tissue disease - Dry eye, Sicca

Design outcomes

Primary

MeasureTime frame
The principal objective of the study is to investigate the aspheric profile using ReLEx hismile as a treatment option compared to the current ReLEx smile spherical profile. The focus of the research is to measure the change in the so called spherical aberration as a measure of optical quality. Spherical aberration will be measured using both a corneal topographer and a wavefront aberrometer at each visit.

Secondary

MeasureTime frame
The secondary objective of the study will be an extensive analysis of the refractive and visual outcomes at each follow-up visit. This analysis will follow the routine analysis of data in refractive surgery research. The study will also include analysis of corneal surface data (topography) and whole eye optics (wavefront aberrometry). Objective and subjective visual quality will also be assessed by measuring contrast sensitivity and by using a patient questionnaire pre- and postoperative.

Countries

Latvia, Switzerland, United Kingdom

Contacts

Public ContactDan Reinstein

London Vision Clinic Laser Eye Surgery

dzr@londonvisionclinic.com+44 20 7224 1005

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026